Eli Lilly and Company Reports $303M In Q3 2026 Special Charges, Bringing 9-Month Total To $1.3B, Primarily Driven By Intangible Asset Impairment, Acquisition Costs And Litigation

뉴스 본문을 불러오고 있어요.

Eli Lilly and Company Reports $303M In Q3 2026 Special Charges, Bringing 9-Month Total To $1.3B, Primarily Driven By Intangible Asset Impairment, Acquisition Costs And Litigation | 웨이프 WAPE

Eli Lilly and Company Reports $303M In Q3 2026 Special Charges, Bringing 9-Month Total To $1.3B, Primarily Driven By Intangible Asset Impairment, Acquisition Costs And Litigation

기사 요약

관련 종목

댓글 —